



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

PPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION N
10/627,555	07/25/2003	Martin S. Linsell	P-154-US1	3562
27038 7	590 10/22/2004		EXAM	INER
THERAVAN	CE, INC. Y BOULEVARD		KUMAR, SH	AILENDRA
SOUTH SAN FRANCISCO, CA 94080			ART UNIT	PAPER NUMBER
			1621	
			DATEMAN 10 10/00/000	

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)			
	10/627,555	LINSELL ET AL.			
Office Action Summary	Examiner	Art Unit			
	SHAILENDRA - KUMAR	1621			
The MAILING DATE of this community Period for Reply	nication appears on the cover sheet with	the correspondence address			
A SHORTENED STATUTORY PERIOD F THE MAILING DATE OF THIS COMMUN - Extensions of time may be available under the provision after SIX (6) MONTHS from the mailing date of this com - If the period for reply specified above is less than thirty (- If NO period for reply is specified above, the maximum is - Failure to reply within the set or extended period for repl Any reply received by the Office later than three months earned patent term adjustment. See 37 CFR 1.704(b).	IICATION. s of 37 CFR 1.136(a). In no event, however, may a repl munication. 30) days, a reply within the statutory minimum of thirty (3 tatutory period will apply and will expire SIX (6) MONTH by will, by statute, cause the application to become ABAN	y be timely filed 30) days will be considered timely. S from the mailing date of this communication. IDONED (35 U.S.C. § 133).			
Status					
1) Responsive to communication(s) filed on <u>25 July 2003</u> .					
2a) This action is FINAL.	This action is FINAL . 2b) ☐ This action is non-final.				
3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is					
closed in accordance with the pract	ice under <i>Ex parte Quayle</i> , 1935 C.D. 1	1, 453 O.G. 213.			
Disposition of Claims					
4) ⊠ Claim(s) 1-40 is/are pending in the 4a) Of the above claim(s) is/a 5) □ Claim(s) is/are allowed. 6) □ Claim(s) is/are rejected. 7) □ Claim(s) is/are objected to. 8) ⊠ Claim(s) 1-40 are subject to restrict	are withdrawn from consideration.				
Application Papers					
9) The specification is objected to by the	e Examiner.				
10) The drawing(s) filed on is/are: a) accepted or b) objected to by the Examiner.					
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).					
11) The oath or declaration is objected t	g the correction is required if the drawing(s) o by the Examiner. Note the attached C				
Priority under 35 U.S.C. § 119					
2. Certified copies of the priority3. Copies of the certified copies	documents have been received. documents have been received in App of the priority documents have been re- onal Bureau (PCT Rule 17.2(a)).	lication No ceived in this National Stage			
Attachment(s)					
1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (F3) Information Disclosure Statement(s) (PTO-1449 or Paper No(s)/Mail Date	TO-948) Paper No(s)/M	mary (PTO-413) ail Date mal Patent Application (PTO-152)			

Art Unit: 1621

1. Restriction to one of the following inventions is required under 35 U.S.C. 121:

- I. Claims 1-11 and 20-26, drawn to compound and composition, classified in class 564 and 514, subclass 218 and 629 respectively.
- II. Claims12-14, drawn to combination of compound of claim 1 with other therapeutic agents, classified in class 552, subclass various.
- III. Claims 15-19, drawn to process of making the compounds and the product by the process, classified in class 564, subclass 4.
- IV. Claim 27, drawn to a kit, classified in class 206, subclass 569.
- V. Claims 28-30, drawn to process of preparing a composition for nabulizer,
 classified in class 601, subclass various.
- VI. Claims 31-37, drawn to a method of treating diseases associated with beta-2 adrenergic receptor activity, classified in class 514, subclass 630.
- VII. Claim38-40, drawn to a process of preparing an intermediate, classified in class 564, subclass 305.

The inventions are distinct, each from the other because of the following reasons:

2. Inventions I and II are related as combination and subcombination. Inventions in this relationship are distinct if it can be shown that (1) the combination as claimed does not require the particulars of the subcombination as claimed for patentability, and (2) that the subcombination has utility by itself or in other combinations (MPEP § 806.05(c)). In the instant case, the combination as claimed does not require the particulars of the subcombination as claimed because the compounds itself can be used to treat various diseases associated with beta-2 adrenergic conditions. The

Application/Control Number: 10/627,555

Art Unit: 1621

subcombination has separate utility such as using as anti-inflammatory or anticholinergic agent.

- 3. Inventions III and I are related as process of making and product made. The inventions are distinct if either or both of the following can be shown: (1) that the process as claimed can be used to make other and materially different product or (2) that the product as claimed can be made by another and materially different process (MPEP § 806.05(f)). In the instant case the product as claimed can be materially prepared by crystallizing in other solvents for example propanol or ethanol etc.
- 4. Inventions V and I are related as process of making and product made. The inventions are distinct if either or both of the following can be shown: (1) that the process as claimed can be used to make other and materially different product or (2) that the product as claimed can be made by another and materially different process (MPEP § 806.05(f)). In the instant case the composition as claimed can be made by materially different process such as by dissolving the compound in water and adjusting the pH by acid or base as required.
- 5. Inventions I and VI are related as product and process of use. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the process for using the product as claimed can be practiced with another materially different product or (2) the product as claimed can be used in a materially different process of using that product (MPEP § 806.05(h)). In the instant case the product as claimed can be used in a materially different process of using such as disclosed on page 3 of the instant specification.

Application/Control Number: 10/627,555

Art Unit: 1621

- 6. Inventions I, and VII are unrelated. Inventions are unrelated if it can be shown that they are not disclosed as capable of use together and they have different modes of operation, different functions, or different effects (MPEP § 806.04, MPEP § 808.01). In the instant case the different inventions of Group VII is drawn to the preparation of an aminophenyl ethyl amine derivative which is unrelated to the claimed compounds and composition of Group I.
- 7. Inventions I and IV are related as subcombinations disclosed as usable together in a single combination. The subcombinations are distinct from each other if they are shown to be separately usable. In the instant case, invention I has separate utility such as administering the composition in a metered dose. See MPEP § 806.05(d).
- 8. Because these inventions are distinct for the reasons given above and have acquired a separate status in the art because of their recognized divergent subject matter and have been classified in separate class, subclass according to US classification, restriction for examination purposes as indicated is proper.
- 9. A telephone call was made to Roberta Saxon on 9/14/04 to request an oral election to the above restriction requirement, but did not result in an election being made.

Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

10. Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one

Art Unit: 1621

or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

11. Any inquiry concerning this communication or earlier communications from the examiner should be directed to SHAILENDRA - KUMAR whose telephone number is (571)272-0640. The examiner can normally be reached on Mon-Thur 8:00-5:30, Alt Fri.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Johann Richter can be reached on (571)272-0646. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

SHAILENDRA - KUMAR Primary Examiner Art Unit 1621

S.Kumar 10/21/04